Tango Therapeutics TNGX Increase Decrease In Accrued Expenses And Other Liabilities
Increase Decrease In Accrued Expenses And Other Liabilities at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept tngx:IncreaseDecreaseInAccruedExpensesAndOtherLiabilities.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's increase decrease in accrued expenses and other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's increase decrease in accrued expenses and other liabilities?
- Tango Therapeutics (TNGX) reported increase decrease in accrued expenses and other liabilities of -$8.69M in Q1 2026.
- How has Tango Therapeutics's increase decrease in accrued expenses and other liabilities changed year-over-year?
- Tango Therapeutics's increase decrease in accrued expenses and other liabilities decreased by 41.9% year-over-year, from -$6.12M to -$8.69M.
- What is the long-term trend for Tango Therapeutics's increase decrease in accrued expenses and other liabilities?
- Over 2 years (2021 to 2024), Tango Therapeutics's increase decrease in accrued expenses and other liabilities has grown at a -45.6% compound annual growth rate (CAGR), from $3.83M to $1.13M.
- What does increase decrease in accrued expenses and other liabilities mean?
- Represents the net change in short-term obligations and accrued liabilities during the reporting period. This metric reflects the timing differences between when expenses are incurred and when the actual cash outflow occurs, serving as a component of working capital adjustments. For a biotech firm, it highlights shifts in operational payables related to research and development activities.